https://www.fortunebusinessinsights.com/industry-reports/injectable-drug-delivery-market-101044#summary


https://www.fortunebusinessinsights.com/industry-reports/teleradiology-market-100284

The global injectable drug delivery market was valued at USD 483.5 billion in 2019 and is expected to
grow to USD 2,651.3 billion by 2032, reflecting a CAGR of 13.1% from 2020 to 2032. In 2019, North
America accounted for a market size of USD 172.67 billion, representing a 35.71% share.
The injectable drug delivery market is a vital segment of the pharmaceutical industry, focused on
delivering medications through injection to ensure rapid and effective treatment. This market has grown
substantially due to the increasing prevalence of chronic diseases, the rise of biologic therapies, and a
shift toward patient-friendly delivery systems. Injectable devices such as prefilled syringes,
autoinjectors, and wearable injectors have improved the ease and safety of drug administration,
especially for self-care at home. As healthcare systems continue to prioritize personalized and efficient
treatment options, the injectable drug delivery market is expected to remain a key driver of innovation,
offering solutions that enhance patient compliance and improve therapeutic outcomes worldwide.

Tariff Impact Analysis for Injectable Drug Delivery Market:
https://www.fortunebusinessinsights.com/industry-reports/teleradiology-market-100284

Market Segmentation
 By Product Type: Includes prefilled syringes, auto-injectors, pen injectors, needle-free injectors,
and conventional syringes.
 By Usage: Divided into curative care and preventive care segments.
 By Route of Administration: Covers intramuscular, subcutaneous, and intravenous routes.
 By End User: Hospitals, homecare settings, ambulatory surgical centers, and clinics are the
major end users in the injectable drug delivery market.
 By Application: Encompasses oncology, diabetes, hormonal disorders, cardiovascular diseases,
and others.

List Of Key Companies Profiled In Injectable Drug Delivery Market:
 BD (New Jersey, U.S)
 SHL Medical AG (Switzerland, Europe)
 Schott AG (Germany, Europe)
 West Pharmaceutical Services, Inc. (Pennsylvania, U.S)
 Pfizer Inc. (New York, U.S)

Insulet Corporation (Massachusetts, U.S)
 Elcam Medical (Israel, Middle East)
 Eli Lilly and Company (Indiana, U.S)
 Ypsomed AG (Switzerland, Europe)
 Gerresheimer AG (Germany, Europe)
 Baxter International Inc (Illinois, U.S)
 Other Players

Market Growth
The injectable drug delivery market is witnessing robust growth due to the increasing prevalence of
chronic diseases such as diabetes, cancer, and autoimmune disorders.
Technological advancements in prefilled syringes, auto-injectors, and pen injectors are accelerating the
expansion of the injectable drug delivery market.
Rising demand for self-administration and patient-friendly drug delivery solutions is propelling the
injectable drug delivery market forward.
Biologics and biosimilars are becoming more prominent, significantly boosting the value of the
injectable drug delivery market.
The market is also benefiting from a growing geriatric population that requires efficient and fast-acting
drug delivery methods.

Restraining Factors
Needle-stick injuries and concerns about safety and disposal continue to hinder adoption in the
injectable drug delivery market.
High cost of advanced injectable devices may restrict access in low- and middle-income regions.
Patient non-compliance due to fear of needles or pain can limit market potential.
Stringent regulatory requirements for approval of injectable devices and drugs can delay product
launches.
Limited infrastructure in rural healthcare facilities may reduce the reach of the injectable drug delivery
market.

Regional Analysis
North America leads the injectable drug delivery market due to high healthcare spending, strong
adoption of biologics, and technological advancements.
Europe follows closely, driven by government initiatives, aging population, and the increasing burden of
chronic illnesses.
Asia-Pacific is expected to witness the fastest growth in the injectable drug delivery market due to
expanding healthcare infrastructure and rising awareness among patients.
Latin America is showing moderate growth, primarily supported by improvements in healthcare delivery
systems.
Middle East & Africa have untapped potential but currently face challenges like limited access and
affordability issues in the injectable drug delivery market.ss

Key Industry Developments:
 March 2020 – Becton, Dickinson and Company (BD) successfully completed a 50-subject human
clinical trial for its investigational BD Libertas Wearable Injector.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner - Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:

sales@fortunebusinessinsights.com

U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com